Patent Protection This news was overlooked in November due to the overall market jitters. There were no buyers for much for anything at that time no matter what news was. Very important factor gong forward. If this news was released today it would rocket the SP. The FDA approval given last February has also been severely discounted by the market weakness this past 12 months. This stock should be trading twice the price and then some, and it will.
Medipattern receives U.S. patent for Cadenza technology
2011-11-03 05:45 PT - News Release
Mr. Jeff Collins reports
MEDIPATTERN RECEIVES U.S. PATENT FOR MULTI-MODALITY DETECTION OF LESIONS FURTHERING ITS TECHNOLOGY
The Medipattern Corp. has received United States patent No. 8,014,576 for a "method and system of computer-aided quantitative and qualitative analysis of medical images." The patent relates to the field of computer-aided analysis of medical images and detection of suspicious abnormalities. It defines a method and system for processing medical images obtained from multiple modalities, including analysis of kinetics as well as morphological features and automated detection of abnormalities, and analysis of medical images from multiple modalities.
The patent extends the core technology for Medipattern embodied in its Cadenza platform to analyze and characterize medical images. Medipattern's previous patent, No. 7,783,094, addressed computer-aided detection in medical images which are analyzed, to extract and identify a set of features in the image relevant to a diagnosis. This new patent also covers the combined use of morphological and kinetic features to compute a consolidated assessment of a possible lesion detected in medical imaging. Though the technology was primarily invented for the use of combining the various image modalities in breast imaging (X-ray-based mammography, ultrasound, computed tomography (CT), positron emission tomography (PET/CT), magnetic resonance imaging (MRI), MR spectroscopy (MRS) and nuclear imaging, the patented algorithm can be used in other medical imaging applications where the combination of various modalities can lead to a better understanding of the abnormality as would be the case for vascular imaging studies that use US, CT angiography and MR angiography to diagnose patients. The inventors are Jeffrey Collins, president and chief executive officer of Medipattern, Frederic Lachmann, PhD, chief technology officer of Medipattern, Karen Saghatelyan, and Sandra Stapleton. The technology is under review for patent protection in several other countries globally.
"The new patent solidifies Medipattern's position as a globally recognized leading-edge developer of medical imaging analysis tools. We congratulate the entire team at Medipattern for their accomplishment and their contribution to the furtherance of medical science," commented Janet Sterritt, vice-president of business strategy for Medipattern. "Cadenza is the basis for our B-CAD, B-CADmri and Visualize:Vascular products. B-CADmri technology was subsequently exclusively licensed to Sentinelle Medical, now a Hologic company. The combined capabilities of detection, identification, characterization, rendering and visualization form a medical image analysis tool set that is unique to Medipattern. The combination of being able to identify the lesion in pictures, characterize it in words, measure it analytically and assess its level is highly valued in being able to fully assist physicians in more readily assessing the extent of lesions. Medipattern also adds 3-D rendering with our new vascular product line so that the physician can visualize critical anatomy, providing a new perspective."
2011 upcoming events
- Veith 38th annual symposium, Nov. 16 to 20 with partner Navix Diagnostix;
- RSNA 2011, Nov. 27 to Dec. 2 with partners TomTec and PenRad.